신경 바이오마커 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)
Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer´s, Parkinson´s, Multiple Sclerosis, Autism), By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030
상품코드
:
1726154
리서치사
:
Grand View Research, Inc.
발행일
:
2025년 04월
페이지 정보
:
영문 120 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
신경 바이오 마커 시장의 성장과 동향
Grand View Research, Inc.의 최신 보고서에 따르면 신경 바이오마커 세계 시장 규모는 2025-2030년에 걸쳐 CAGR 12.9%로 성장할 것으로 예상되며, 2030년에는 187억 5,000만 달러에 이를 전망입니다.
신약 개발을 뒷받침하는 신경적 바이오마커의 연구개발에 대한 자금 제공 증가가 시장 성장을 뒷받침할 것으로 예측됩니다.
바이오마커는 신경질환 치료의 개발에 중요한 역할을 하고 있습니다. ALS는 ALS의 새로운 바이오마커 발견에 초점을 맞춘 프로젝트에 1,500만 달러의 연구 자금을 제공할 것이라고 발표했으며, 예측 기간 동안 시장 성장이 가속될 것으로 예측됩니다.
Quanterix Simoa(단일 분자 어레이)와 같이 신호 대 잡음비가 높은 디지털 ELISA 테스트와 같은 기술적으로 진보된 제품을 사용할 수 있습니다. 이 기술은 신경 질환 관련 바이오마커와 관련된 혈액-뇌 장벽 문제를 극복하는 데 도움이 됩니다.
2021년 1월, 뇌진탕을 포함한 외상성 뇌 손상에 대한 최초의 신속한 혈액 검사를 발표했습니다.
이러한 진단 제품에 대한 인지도가 낮고 비용이 높아지고, 특히 신흥 국가나 저개발 국가에서 신경과 의사의 부족과 부재 등의 요인이 이러한 바이오마커에 의한 진단 솔루션의 채용에 영향을 줄 수 있습니다. 세계 신경학 연맹이 WHO 회원국 63/84개국을 대상으로 한 조사에 따르면 31/63개국의 신경과 의사의 대다수는 대도시에 근무하고 있었습니다.
신경 바이오 마커 시장 보고서 하이라이트
- 2024년에는 단백질체학형이 최대 시장 점유율을 차지하고 예측 기간 동안도 우위성을 유지할 것으로 예측됩니다.
- 파킨슨병 부문은 이환율의 상승과 연구개발 활동의 활성화에 의해 최대 시장 점유율을 차지하고 있습니다.
- 최종 용도별로는 연구기관과 기타 부문이 신경바이오마커 시장을 독점했습니다.
- 북미는 미국과 캐나다에 강력한 존재를 가진 시장 진출기업의 존재와 신규 바이오마커 개발을 위한 정부 자금 증가로 시장을 독점하고 있습니다.
- 아시아태평양은 일본과 호주와 같은 선진국에서 기술적으로 선진 진단 제품의 높은 채용률과 중국과 인도와 같은 신흥 경제 국가에서 이러한 제품의 채용 증가로 예측 기간 동안 큰 성장이 예상됩니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 신경 바이오마커 시장의 변수, 동향, 범위
- 신경 바이오마커 시장의 계통 전망
- 침투와 성장의 전망 매핑
- 파이프라인 분석
- 알츠하이머병
- 파킨슨병
- 다발성 경화증
- 자폐증 스펙트럼 장애
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 신경 바이오 마커 : 시장 분석 도구
- 산업 분석 - Porter's Five Forces 분석
- PESTLE 분석
제4장 신경 바이오마커 시장 : 부문 분석, 유형별, 2018-2030년
제5장 신경 바이오마커 시장 : 부문 분석, 용도별, 2018-2030년
제6장 신경 바이오마커 시장 : 부문 분석, 최종 용도별, 2018-2030년
- 신경 바이오 마커 시장 : 최종 용도 변동 분석
제7장 신경 바이오마커 시장 : 지역별 부문 분석, 2018-2030년
- 지역 시장 현황
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
제8장 신경 바이오마커 시장 : 경쟁 분석
- 기업 분류
- 전략 매핑
- 신제품 발매
- 파트너십
- 취득
- 콜라보레이션
- 자금조달
- 2022년 기업의 시장 점유율 분석
- 기업 프로파일
- Abbott
- Johnson & Johnson Services, Inc.
- Bio-Rad Laboratories, Inc.
- Alseres Pharmaceuticals, Inc.
- Banyan Biomarkers, Inc.
- Rules-Based Medicine
- Thermo Fisher Scientific, Inc.
- Diagenic Asa
- Merck & Co., Inc.
- Quanterix
SHW
영문 목차
Neurological Biomarkers Market Growth & Trends:
The global neurological biomarkers market size is expected to reach USD 18.75 billion by 2030, expanding at a CAGR of 12.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increased funding for R&D of neurological biomarkers to boost development of new drugs is expected to impel market growth. National Institute of Neurological Disorders and Stroke provides funding opportunities such as cooperative agreements & development grants for researchers conducting studies related to clinical validation, analytical validation, & biomarker discovery.
Biomarkers play a significant role in the development of drugs for the treatment of neurological diseases. In recent years, there has been a significant rise in investments in the R&D of treatments for neurological diseases. For instance, in December 2020, Target ALS-a nonprofit research foundation-announced research funding of USD 15 million for a project focused on the discovery of novel biomarkers for ALS, which is anticipated to accelerate market growth in the forecast period.
Availability of technologically advanced products such as Quanterix Simoa (single-molecule array), which is a digitized ELISA test with a high signal-to-noise ratio. This technology helps overcome blood-brain barrier issues associated with neurological disease-related biomarkers. Such technological advancements are expected to drive market growth. For instance, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.
Factors such as lack of awareness about such diagnostic products & their high cost and limited availability or absence of neurologists, especially in developing & underdeveloped countries, could affect the adoption of such biomarker-based diagnostic solutions. According to a World Federation of Neurology survey of 63/84 WHO member countries, the majority of neurologists in 31/63 countries worked in major cities. One neurologist was serving a population of about 6,240 to 4,750,000.
Neurological Biomarkers Market Report Highlights:
- In 2024, proteomic type accounted for the largest market share and is anticipated to maintain their dominance over the forecast period as these are essential for accurate diagnosis of disease onset and progression due to the careful detection of posttranslational modifications and protein signatures
- Parkinson's disease segment held the largest market share owing to rising incidence and increasing R&D activities.
- Based on end use, the research organizations and others segment dominated the neurological biomarkers market. Research organizations collaborating for the development of therapeutics for treating neurological disorders utilize biomarkers for assessing the drug tolerance.
- North America dominated the market owing to presence of market players with strong presence in the U.S. & Canada, and increasing government funding for the development of novel biomarkers
- Asia-Pacific is anticipated to witness significant growth over the forecast period owing to high adoption of technologically advanced diagnostic products in developed countries such as Japan & Australia and increasing adoption of these products in developing economies such as China and India.
Table of Contents
Chapter 1 Methodology And Scope
- 1.1 Market Segmentation And Scope
- 1.1.1 Segment Definition
- 1.1.1.1 Application Segment
- 1.1.1.2 Type Segment
- 1.1.1.3 End Use Segment
- 1.2 Regional Scope
- 1.3 Estimates And Forecast Timeline
- 1.4 Objectives
- 1.4.1 Objective - 1
- 1.4.2 Objective - 2
- 1.4.3 Objective - 3
- 1.5 Research Methodology
- 1.6 Information Procurement
- 1.6.1 Purchased Database
- 1.6.2 Gvr's Internal Database
- 1.6.3 Secondary Sources
- 1.6.4 Primary Research
- 1.7 Information Or Data Analysis
- 1.7.1 Data Analysis Models
- 1.8 Market Formulation & Validation
- 1.9 Model Details
- 1.9.1 Commodity Flow Analysis
- 1.10 List Of Secondary Sources
- 1.11 List Of Abbreviations
Chapter 2 Executive Summary
- 2.1 Market Outlook
- 2.2 Application And Type Snapshot
- 2.3 End Use Snapshot
- 2.4 Competitive Landscape Snapshot
Chapter 3 Neurological Biomarkers Market Variables, Trends, And Scope
- 3.1 Neurological Biomarkers Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.2 Penetration And Growth Prospect Mapping
- 3.3 Pipeline Analysis
- 3.3.1 Alzheimer's Disease
- 3.3.2 Parkinson's Disease
- 3.3.3 Multiple Sclerosis
- 3.3.4 Autism Spectrum Disorder
- 3.4 Market Dynamics
- 3.4.1 Market Driver Analysis
- 3.4.1.1 Increasing Prevalence Of Neurological Diseases
- 3.4.1.2 Technological Advancements
- 3.4.1.3 Increased Funding For R&D In Biomarkers
- 3.4.2 Market Restraint Analysis
- 3.4.2.1 Lack Of Consumer Awareness
- 3.4.2.2 Reimbursement Policies
- 3.5 Neurological Biomarkers: Market Analysis Tools
- 3.5.1 Industry Analysis - Porter's
- 3.5.2 Pestle Analysis
Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)
- 4.1 Neurological Biomarkers Market: Type Movement Analysis
- 4.1.1 Genomic
- 4.1.1.1 Genomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 4.1.2 Proteomic
- 4.1.2.1 Proteomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 4.1.3 Metabolomic
- 4.1.3.1 Metabolomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 4.1.5 Imaging
- 4.1.5.1 Imaging Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 4.1.6 Others
- 4.1.6.1 Others Neurological Biomarkers Market, 2018 - 2030 (USD Million)
Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)
- 5.1 Neurological Biomarkers Market: Application Movement Analysis
- 5.1.1 Alzheimer's Disease
- 5.1.1.1 Alzheimer's Disease Market, 2018 - 2030 (USD Million)
- 5.1.2 Parkinson's Disease
- 5.1.2.1 Parkinson's Disease Market, 2018 - 2030 (USD Million)
- 5.1.3 Multiple Sclerosis
- 5.1.3.1 Multiple Sclerosis Market, 2018 - 2030 (USD Million)
- 5.1.4 Autism Spectrum Disorder
- 5.1.4.1 Autism Spectrum Disorder Market, 2018 - 2030 (USD Million)
- 5.1.5 Others
- 5.1.5.1 Others Market, 2018 - 2030 (USD Million)
Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)
- 6.1 Neurological Biomarkers Market: End Use Movement Analysis
- 6.1.1 Research Organizations
- 6.1.1.1 Research Organizations Market, 2018 - 2030 (USD Million)
- 6.1.2 Pharma & Biotech Companies
- 6.1.2.1 Pharma & Biotech Companies Market, 2018 - 2030 (USD Million)
- 6.1.3 Clinical Diagnostics
- 6.1.3.1 Clinical Diagnostics Market, 2018 - 2030 (USD Million)
Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)
- 7.1 Regional Market Snapshot
- 7.2 North America
- 7.2.1 North America Neurological Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.2.2 U.S.
- 7.2.2.1 U.S. Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.2.2.2 Key Country Dynamics
- 7.2.2.3 Regulatory Framework
- 7.2.2.4 Reimbursement Scenario
- 7.2.3 Canada
- 7.2.3.1 Canada Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.2.3.2 Key Country Dynamics
- 7.2.3.3 Regulatory Framework
- 7.2.3.4 Reimbursement Scenario
- 7.2.4 Mexico
- 7.2.4.1 Mexico Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.2.4.2 Key Country Dynamics
- 7.2.4.3 Regulatory Framework
- 7.2.4.4 Reimbursement Scenario
- 7.3 Europe
- 7.3.1 Europe Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.3.2 Uk
- 7.3.2.1 Uk Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.3.2.2 Key Country Dynamics
- 7.3.2.3 Regulatory Framework
- 7.3.2.4 Reimbursement Scenario
- 7.3.3 Germany
- 7.3.3.1 Germany Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.3.3.2 Key Country Dynamics
- 7.3.3.3 Regulatory Framework
- 7.3.3.4 Reimbursement Scenario
- 7.3.4 Spain
- 7.3.4.1 Spain Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.3.4.2 Key Country Dynamics
- 7.3.4.3 Regulatory Framework
- 7.3.4.4 Reimbursement Scenario
- 7.3.5 France
- 7.3.5.1 France Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.3.5.2 Key Country Dynamics
- 7.3.5.3 Regulatory Framework
- 7.3.5.4 Reimbursement Scenario
- 7.3.6 Italy
- 7.3.6.1 Italy Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.3.6.2 Key Country Dynamics
- 7.3.6.3 Regulatory Framework
- 7.3.6.4 Reimbursement Scenario
- 7.3.7 Denmark
- 7.3.7.1 Denmark Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.3.7.2 Key Country Dynamics
- 7.3.7.3 Regulatory Framework
- 7.3.7.4 Reimbursement Scenario
- 7.3.8 Sweden
- 7.3.8.1 Sweden Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.3.8.2 Key Country Dynamics
- 7.3.8.3 Regulatory Framework
- 7.3.8.4 Reimbursement Scenario
- 7.3.9 Norway
- 7.3.9.1 Norway Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.3.9.2 Key Country Dynamics
- 7.3.9.3 Regulatory Framework
- 7.3.9.4 Reimbursement Scenario
- 7.4 Asia Pacific
- 7.4.1 Asia-Pacific Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.4.2 Japan
- 7.4.2.1 Japan Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.4.2.2 Key Country Dynamics
- 7.4.2.3 Regulatory Framework
- 7.4.2.4 Reimbursement Scenario
- 7.4.3 China
- 7.4.3.1 China Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.4.3.2 Key Country Dynamics
- 7.4.3.3 Regulatory Framework
- 7.4.3.4 Reimbursement Scenario
- 7.4.4 India
- 7.4.4.1 India Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.4.4.2 Key Country Dynamics
- 7.4.4.3 Regulatory Framework
- 7.4.4.4 Reimbursement Scenario
- 7.4.5 South Korea
- 7.4.5.1 South Korea Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.4.5.2 Key Country Dynamics
- 7.4.5.3 Regulatory Framework
- 7.4.5.4 Reimbursement Scenario
- 7.4.6 Thailand
- 7.4.6.1 Thailand Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.4.6.2 Key Country Dynamics
- 7.4.6.3 Regulatory Framework
- 7.4.6.4 Reimbursement Scenario
- 7.4.7 Australia
- 7.4.7.1 Australia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.4.7.2 Key Country Dynamics
- 7.4.7.3 Regulatory Framework
- 7.4.7.4 Reimbursement Scenario
- 7.5 Latin America
- 7.5.1 Latin America Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.5.2 Brazil
- 7.5.2.1 Brazil Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.5.2.2 Key Country Dynamics
- 7.5.2.3 Regulatory Framework
- 7.5.2.4 Reimbursement Scenario
- 7.5.3 Argentina
- 7.5.3.1 Argentina Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.5.3.2 Key Country Dynamics
- 7.5.3.3 Regulatory Framework
- 7.5.2.4 Reimbursement Scenario
- 7.6 MEA
- 7.6.1 MEA Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.6.2 South Africa
- 7.6.2.1 South Africa Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.6.2.2 Key Country Dynamics
- 7.6.2.3 Regulatory Framework
- 7.6.2.4 Reimbursement Scenario
- 7.6.3 Saudi Arabia
- 7.6.3.1 Saudi Arabia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.6.3.2 Key Country Dynamics
- 7.6.3.3 Regulatory Framework
- 7.6.3.4 Reimbursement Scenario
- 7.6.4 UAE
- 7.6.4.1 UAE Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.6.4.2 Key Country Dynamics
- 7.6.4.3 Regulatory Framework
- 7.6.2.4 Reimbursement Scenario
- 7.6.5 Kuwait
- 7.6.5.1 Kuwait Neurological Biomarkers Market, 2018 - 2030 (USD Million)
- 7.6.5.2 Key Country Dynamics
- 7.6.5.3 Regulatory Framework
- 7.6.5.4 Reimbursement Scenario
Chapter 8 Neurological Biomarkers Market: Competitive Analysis
- 8.1 Company Categorization
- 8.2 Strategy Mapping
- 8.2.1 New Product Launch
- 8.2.2 Partnerships
- 8.2.3 Acquisition
- 8.2.4 Collaboration
- 8.2.5 Funding
- 8.3 Company Market Share Analysis, 2022
- 8.4 Company Profiles
- 8.4.1 Abbott
- 8.4.1.1 Company Overview
- 8.4.1.2 Financial Performance
- 8.4.1.3 Product Benchmarking
- 8.4.1.4 Strategic Initiatives
- 8.4.2 Johnson & Johnson Services, Inc.
- 8.4.2.1 Company Overview
- 8.4.2.2 Financial Performance
- 8.4.2.3 Product Benchmarking
- 8.4.2.4 Strategic Initiatives
- 8.4.3 Bio-Rad Laboratories, Inc.
- 8.4.3.1 Company Overview
- 8.4.3.2 Financial Performance
- 8.4.3.3 Product Benchmarking
- 8.4.3.4 Strategic Initiatives
- 8.4.4 Alseres Pharmaceuticals, Inc.
- 8.4.4.1 Company Overview
- 8.4.4.2 Product Benchmarking
- 8.4.5 Banyan Biomarkers, Inc.
- 8.4.5.1 Company Overview
- 8.4.5.2 Product Benchmarking
- 8.4.5.3 Strategic Initiatives
- 8.4.6 Rules-Based Medicine
- 8.4.6.1 Company Overview
- 8.4.6.2 Financial Performance
- 8.4.6.3 Product Benchmarking
- 8.4.6.4 Strategic Initiatives
- 8.4.7 Thermo Fisher Scientific, Inc.
- 8.4.7.1 Company Overview
- 8.4.7.2 Financial Performance
- 8.4.7.3 Product Benchmarking
- 8.4.7.4 Strategic Initiatives
- 8.4.8 Diagenic Asa
- 8.4.8.1 Company Overview
- 8.4.8.2 Product Benchmarking
- 8.4.9 Merck & Co., Inc.
- 8.4.9.1 Company Overview
- 8.4.9.2 Financial Performance
- 8.4.9.3 Product Benchmarking
- 8.4.9.4 Strategic Initiatives
- 8.4.10 Quanterix
- 8.4.10.1 Company Overview
- 8.4.10.2 Product Benchmarking
- 8.4.10.3 Strategic Initiatives
관련자료
